19.87
전일 마감가:
$19.93
열려 있는:
$19.88
하루 거래량:
366.91K
Relative Volume:
0.50
시가총액:
$1.02B
수익:
$312.78M
순이익/손실:
$-143.56M
주가수익비율:
-7.3866
EPS:
-2.69
순현금흐름:
$1.22M
1주 성능:
+4.03%
1개월 성능:
-0.70%
6개월 성능:
+71.74%
1년 성능:
-19.55%
Caredx Inc Stock (CDNA) Company Profile
명칭
Caredx Inc
전화
415-287-2300
주소
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CDNA
Caredx Inc
|
19.87 | 1.03B | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2025-08-26 | 개시 | William Blair | Mkt Perform |
| 2025-01-15 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2024-08-28 | 개시 | Wells Fargo | Underweight |
| 2024-08-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-05-13 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-05-01 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-11-09 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-08-15 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2023-03-03 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2023-03-03 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2021-07-20 | 재개 | BTIG Research | Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-26 | 개시 | BTIG Research | Buy |
| 2020-06-19 | 재확인 | H.C. Wainwright | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-05-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2019-02-15 | 개시 | Jefferies | Buy |
| 2018-10-23 | 재개 | Raymond James | Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Neutral |
| 2017-11-27 | 개시 | H.C. Wainwright | Buy |
| 2016-06-14 | 재확인 | Mizuho | Buy |
| 2015-09-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-09-25 | 개시 | Craig Hallum | Buy |
| 2015-03-18 | 재확인 | Mizuho | Buy |
모두보기
Caredx Inc 주식(CDNA)의 최신 뉴스
(CDNA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
EV Market: Can CareDx Inc maintain sales growthJuly 2025 Snapshot & Low Drawdown Trading Techniques - baoquankhu1.vn
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference - BioSpace
Is CareDx (CDNA) Quietly Redefining Its Moat With AlloHeme’s Early Relapse Detection Breakthrough? - Yahoo Finance
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Beh - GuruFocus
Zweig DiMenna Associates LLC Buys 348,400 Shares of CareDx, Inc. $CDNA - MarketBeat
CareDx (CDNA) Projected to Post Earnings on Tuesday - MarketBeat
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT - Zacks Investment Research
Does ACROBAT AlloHeme Validation Broaden CareDx’s (CDNA) Transplant+ Thesis Into Hematology-Oncology? - simplywall.st
Assessing CareDx (CDNA) Valuation After Positive AlloHeme Clinical Validation Results - Yahoo Finance
CareDx Seeks High Court Review Of $45M False Ad Case - Law360
CareDx Announces Clinical Validation Results for AlloHeme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy - marketscreener.com
CareDx Expands “Transplant Plus” Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data - MarketBeat
Page not foundAirwhon - MarketBeat
Panic Selling: Will CareDx Inc (1K9) stock benefit from infrastructure billQuarterly Trade Review & Risk Managed Investment Strategies - mfd.ru
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy - 01net
CareDx, Inc. $CDNA Stock Holdings Lessened by New York State Common Retirement Fund - MarketBeat
US Market Wrap: Whats the RSI of CareDx Inc stockJuly 2025 Movers & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - ChartMill
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Trends: What is the dividend yield of CareDx IncJuly 2025 Patterns & AI Enhanced Trading Alerts - baoquankhu1.vn
Liquidity Mapping Around (CDNA) Price Events - Stock Traders Daily
CareDx (NASDAQ:CDNA) Cut to "Hold" at Wall Street Zen - MarketBeat
Can CareDx (CDNA) Turn AlloHeme’s ACROBAT Data Into a Durable Precision-Transplant Moat? - simplywall.st
Lobbying Update: $15,000 of CAREDX lobbying was just disclosed - Quiver Quantitative
Short Covering: Can CareDx Inc keep up with sector leadersChart Signals & Free Reliable Trade Execution Plans - baoquankhu1.vn
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings - BioSpace
Momentum Shift: Will CareDx Inc stock benefit from M AWeekly Trend Summary & Reliable Volume Spike Alerts - baoquankhu1.vn
RSI Check: Will First Busey Corporation outperform small cap indexes2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Price Action: Does FDMT align with a passive investing strategyMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
CareDx CEO Sells Nearly 20,000 Shares in Open Market Transactions - Intellectia AI
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 - The Globe and Mail
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 - The Motley Fool
Did Strong 2025 Revenue Growth and 10x Genomics Deal Just Shift CareDx's (CDNA) Investment Narrative? - Yahoo Finance
CareDx President and CEO Sells 19,000 Shares for $412,000 - The Globe and Mail
CareDx, Inc. $CDNA is Gagnon Advisors LLC's 8th Largest Position - MarketBeat
CareDx, Inc. $CDNA Position Increased by Gagnon Securities LLC - MarketBeat
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Chartmill
Can CareDx Inc deliver consistent dividendsDollar Strength & Advanced Swing Trade Entry Alerts - mfd.ru
Death Cross: Is CareDx Inc a play on infrastructure spendingCPI Data & AI Based Buy and Sell Signals - baoquankhu1.vn
Aug Update: Can CareDx Inc beat the S P 5002025 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Is CareDx’s Upgraded 2025 Revenue Outlook Altering The Investment Case For CareDx (CDNA)? - Sahm
CareDx CEO Hanna sells $412,222 in shares By Investing.com - Investing.com India
CareDx CEO Hanna sells $412,222 in shares - Investing.com
Insider Sell: Hanna John Walter JR Sells Shares of CareDx Inc (C - GuruFocus
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 19,280 Shares - MarketBeat
CareDx, Inc. (CDNA) Stock Analysis: A Healthcare Innovator With 4.66% Upside Potential - DirectorsTalk Interviews
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 10,156 Shares - MarketBeat
Tech Rally: What is the dividend yield of CareDx IncJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Sentiment Review: Can CareDx Inc generate free cash flow2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
Caredx Inc (CDNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):